aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
CancerIQ's mission is to leverage genetic information to predict, pre-empt, and prevent diseases, with an initial focus on cancer. Their precision prevention platform aids healthcare providers in utilizing genetic data to identify high-risk patients and implement proactive care strategies. This approach aims to enhance patient outcomes and reduce the overall burden of disease.
CancerIQ has achieved significant milestones in integrating genetic insights into clinical practice, contributing to early detection and prevention efforts. Their platform is utilized by numerous healthcare providers, demonstrating its impact on improving patient care. Notable investors include prominent venture capital firms, underscoring the company's potential in revolutionizing disease prevention.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Healthcare, Risk Assessment
Technology
AI, Machine Learning
Tags
Healthtech, SaaS
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was CancerIQ founded?
CancerIQ was founded in 2013.
Where is CancerIQ’s headquarters located?
CancerIQ’s headquarters is located in Chicago, IL, US.
How many employees does CancerIQ have?
CancerIQ has 49 employees as of Feb 4, 2024.
How much has CancerIQ raised to-date?
As of July 05, 2023, CancerIQ has raised a total of $20M (USD) since Nov 10, 2023.
Add Comparison
Total Raised to Date
$20M
USD
Last Update Nov 10, 2023
Total Employees Over Time
49
As of Feb 2024
CancerIQ Address
515 North State
Suite 1075
Chicago,
Illinois
60654
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts